Related Experiment Video
Updated: Oct 7, 2025
12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
34.8K
Variable roles of interleukin-17F in different cancers
Tiina Mikkola1,2, Rabeia Almahmoudi1,2, Tuula Salo1,2,3,4,5
1Department of Oral and Maxillofacial Diseases, University of Helsinki, Clinicum, Biomedicum Helsinki 1, C223b, P.O. Box 63 (Haartmaninkatu 8), 00014, Helsinki, Finland.
BMC Cancer
|January 11, 2022
Summary
Interleukin-17F (IL-17F) exhibits dual roles in cancer, acting as both an anti-tumor and pro-tumor agent. Its specific function depends on the cancer type and IL-17F
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- The Interleukin-17 (IL-17) family comprises six cytokines crucial in inflammation and cancer progression.
- While IL-17A is recognized for its protumorigenic effects, IL-17F's role remains less understood.
- This review focuses on the multifaceted functions of IL-17F in various cancer types.
Purpose of the Study:
- To systematically review the literature on the role of IL-17F in cancer.
- To analyze IL-17F's protein and mRNA expression, polymorphisms, and functional impact.
- To elucidate the dual anti- and protumorigenic activities of IL-17F.
Main Methods:
- Systematic review adhering to established guidelines.
- Comprehensive literature search across PubMed, Ovid Medline, Scopus, and Cochrane libraries.
- Inclusion of 79 articles investigating IL-17F in cancer.
Main Results:
- IL-17F demonstrates context-dependent roles, acting as either an anti-tumor or pro-tumor factor.
- Protective effects of IL-17F protein observed in oral and pancreatic cancers.
- Protumorigenic effects of IL-17F noted in prostate and bladder cancers.
- Mechanisms include modulation of angiogenesis, cell proliferation, migration, invasion, and inflammation.
- No significant correlation found between IL-17F polymorphisms and cancer outcomes.
Conclusions:
- IL-17F is a complex cytokine with diverse biological activities in cancer.
- Further well-designed studies are needed to clarify IL-17F's molecular mechanisms in different cancers.
- Heterogeneity in study designs limits direct interstudy comparisons and necessitates standardized research approaches.
Related Concept Videos
01:24T Cell Types and Functions
1.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.5K
01:27Tumor Immunotherapy
719
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
719
01:20The JAK-STAT Signaling Pathway
9.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.5K
02:26NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K